Grants for Public housing authorities - Federal

This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Transition to the R33 phase is not guaranteed for all grants awarded under this FOA. Continuation from the R21 phase to the R33 phase will be determined by AHRQ staff based on progress achieved in the R21 phase and factors such as program priorities and availability of funds.

The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.The purpose of this Funding Opportunity Announcement (FOA) is to support epidemiologic studies that utilize creative and innovative approaches to studying vision diseases and disorders with high public impact and whose findings will inform prevention and treatment strategies as well as basic sciences research. Background: Clinical vision research projects, including epidemiologic studies, are part of NEI’s core strategy for improving visual health and decreasing visual impairment in populations through research on the burden of disease, its causes, diagnosis, prevention, treatment and rehabilitation. Projects should focus on NEI’s mission to protect and improve visual health including, but not limited to: Determining the burden of eye diseases and their visual outcomes in a changing population, particularly disparities in the burden and the influences of sociocultural, environmental, economic, and demographic factors. Improving early diagnosis of ocular diseases and their underlying processes through new screening and detection strategies. Determining risk factors for ocular diseases. Identifying and assessing strategies that will overcome barriers to eye care and convert evidence-based findings into improved patient and population outcomes. Studying the interplay of factors that exacerbate or mitigate risk for eye diseases. The NEI encourages applications to support ocular epidemiologic research. These projects are supported under the cooperative agreement mechanism. Applicants are strongly encouraged to contact Scientific/Research staff as plans for an application are being developed (see Section VII, Agency Contacts), preferably no later than 12 weeks prior to the anticipated application submission date.

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.

The Green and Resilient Retrofit Program (GRRP) is authorized and funded by Section 30002 of the Inflation Reduction Act of 2022, (Public Law 117-169) (the IRA), titled Improving Energy Efficiency or Water Efficiency or Climate Resilience of Affordable Housing. The program seeks to amplify recent technological advancements in utility efficiency and energy generation, bring a new focus on preparing for climate hazards by reducing residents and properties exposure to hazards, and protecting life, livability, and property when disaster strikes. GRRP is the first HUD program to simultaneously invest in energy efficiency, energy generation, and climate resilience strategies specifically in HUD-assisted multifamily housing. All of the investments under the GRRP will be made in affordable housing communities serving low-income families in alignment with the Administrations Justice 40 goals.HUD is offering GRRP funding through three separate cohorts designed to meet the different needs of HUDs assisted multifamily portfolio. Round One of the GRRP consists of three cohorts of awards, implemented through three parallel Notices of Funding Opportunity (NOFOs):The Elements NOFO provides modest awards designed to add proven and highly impactful climate resilience and carbon reduction measures to the construction scopes of in-progress recapitalization transactions.The Leading Edge NOFO provides funding to Owners aiming to quickly meet ambitious carbon reduction and resilience goals without requiring extensive collaboration with HUD.The Comprehensive NOFO provides funding to initiate recapitalization investments designed from inception around deep retrofits, focused on innovative energy efficiency and greening measures, renewable energy generation, use of structural building materials with lower embodied carbon, and climate resilience investments. Comprehensive Awards are designed for the widest range of properties, including those that have not yet developed a recapitalization plan.To the greatest extent feasible, these approaches will:Substantially improve energy and water efficiency, including moving properties toward net zero, zero energy ready, or zero over time energy performance; Address climate resilience, including synergies that can be achieved between efficiency and resilience investments;Enhance indoor air quality and resident health;Implement the use of zero-emission electricity generation and energy storage;Minimize embodied carbon and incorporate low-emission building materials or processes; andSupport building electrification.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

This funding opportunity supports research that provides critical data to help the FDA regulate tobacco products, targeting a wide range of organizations, including nonprofits, educational institutions, and community groups, to improve public health outcomes related to tobacco use.

This funding opportunity supports innovative researchers in the U.S. who are tackling significant challenges in diabetes, metabolic diseases, digestive disorders, and nutrition, with the goal of advancing groundbreaking scientific understanding and treatment.

This grant provides funding for research initiatives that enhance the coordination of human services to improve the well-being of low-income families and those from underserved communities over a five-year period.

This funding opportunity supports postdoctoral researchers from underrepresented groups in cancer research as they transition to independent faculty positions, providing salary and research funding to help establish their own research programs.

Questions regarding this Funding Opportunity Announcement (FOA) Forecast may be emailed to SCSEP.OGM@dol.gov; however, please note there is limited information that may be shared with the public, as this FOA is currently under development. We encourage prospective applicants and interested parties to use the Grants.gov subscription option to register for future updates provided for this particular FOA.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

This funding opportunity provides financial support for researchers to analyze and integrate existing data to better understand cancer risk, prevention, and treatment outcomes, particularly focusing on innovative methodologies and addressing health disparities.

With this solicitation, BJA seeks to support new and innovative strategies for preventing and reducing crime, improving community safety, and strengthening criminal justice system outcomes. BJA seeks to accomplish this by promoting collaborations with the field to identify, define, and respond to emerging or chronic crime problems or justice system challenges. BJA is looking for strategies that address these issues, including trying new approaches, addressing gaps in responses, building or translating research knowledge, or building capacity.

This funding opportunity supports multidisciplinary research aimed at improving the understanding and treatment of asthma and allergic diseases, inviting applications from various institutions and organizations involved in clinical and translational research.

This funding opportunity supports innovative research projects that explore how T-cells contribute to HIV infection and related brain complications, targeting researchers from various institutions and organizations.

This funding opportunity supports innovative educational projects that engage K-12 students and teachers in the biomedical and behavioral sciences, particularly targeting individuals from diverse and underrepresented backgrounds.

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

This cooperative agreement would establish a Center for Home-based Child Care Research to support research about home-based child care (HBCC) in states, territories, This cooperative agreement would establish a Center for Home-based Child Care Research to support research about home-based child care (HBCC) in states, territories, tribes, and/or local community contexts. The purpose of the Center is to provide leadership, build research capacity in the field, and offer support in the development and facilitation of local research to improve understanding of HBCC settings and providers as well as access by the families who seek and utilize HBCC. This research center would promote sound research examining HBCC supply and the factors that support or suppress the availability of HBCC in communities. In addition, this Center would advance the fields understanding of HBCC engagement in public programs and quality improvement efforts. The Centers activities would build research and evaluation capacity in the field and support research in states, territories, and/or tribes that could inform local initiatives designed to sustain and strengthen HBCC.HBCC providers, or individuals and small business owners paid to provide child care in private residences or homes, are an essential segment of the child care landscape. They constitute the largest portion of the child care and early education (CCEE) workforce and serve the vast majority of children birth through school-age who are in regular nonparental care. It is critical for the Administration for Children and Families and for local communities to learn more about HBCC providers, both the individuals providing the care and the characteristics of the programs where they provide child care, in order to inform federal efforts and state, territory, tribal and/or local initiatives to increase access to safe and high-quality child care particularly for families with lower-incomes and working families. The Center would promote sound research examining HBCC and the factors that support or suppress the availability of HBCC in states, territories, and/or tribes. In addition, this Center would advance the fields understanding of HBCC providers engagement in publicly funded programs (e.g., child care subsidies, Head Start) and quality improvement efforts (e.g., Quality Rating and Improvement Systems (QRIS), quality initiatives (QI), and continuous quality improvement (CQI) initiatives). The Centers activities would build research and evaluation capacity in the field and support research in state, territories and/or tribes that could inform local initiatives designed to sustain and strengthen the supply of HBCC. This Center would ideally bring together a team that has experience investigating HBCC, evaluating Child Care and Development Fund (CCDF) program and policies, and assessing the needs and experiences of families with lower-incomes, in tribal communities, and of historically marginalized populations. This Center would be equipped to strengthen the ability of local research partnerships to conduct model research projects that effectively address questions concerning HBCC in local contexts, while contributing to broader understanding in the field about HBCC.